

FREEDOM OF INFORMATION REQUEST

RF23-774

We can confirm East Kent Hospitals University NHS Foundation Trust (EKHUFT) holds the information you have requested. Please see the responses in bold.

1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?

Ipilimumab (monotherapy)	0
Nivolumab (monotherapy)	0
Nivolumab AND Ipilimumab (combination)	2
Pembrolizumab	2
Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)	4
Other active systemic anti-cancer therapy	0

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal cell carcinoma?

Nivolumab (monotherapy)	0
Nivolumab + Ipilimumab	0
Nivolumab + Cabozantinib	0
Avelumab + Axitinib	0

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

3. In the past 3 months, how many patients have been initiated* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer:

Nivolumab monotherapy or in combination with Ipilimumab	1
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	0
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	1

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

(DATE OF RESPONSE: 19 DECEMBER 2023)